Patient A
Patient A
Patient A
Patient A
Patient B
Patient B
Patient B
Patient B
Patient C
Patient C
Patient C
Patient C
Patient C
Patient C
Brainstem glioma is now recognized as a heterogeneous group requiring formal histological and molecular diagnosis rather than imaging-based diagnosis alone, with diffuse midline glioma H3 K27-altered being the most common formal diagnosis
Clinical presentation duration is critically important: diffuse infiltrating tumors present acutely (days) with rapid symptom progression, while focal gliomas have more gradual symptom onset
Multiple concurrent cranial nerve palsies suggest diffuse infiltrating disease, whereas single or limited nerve involvement suggests more focal tumor
Location strongly predicts prognosis and treatment approach: mesencephalic tumors are lower grade, pontine tumors are most common with worst prognosis (10% 5-year survival), and medullary tumors are rare
Surgical management depends critically on tumor morphology: exophytic and cervicomedullary tumors may be surgically resectable with better outcomes, but diffuse infiltrating pontine gliomas are not surgical candidates and rely on radiation therapy
Stereotactic biopsy is now more frequently obtained to establish H3 K27 mutation status and grade, guiding prognosis and treatment decisions
When reporting a brainstem mass, clearly distinguish between diffuse infiltrating glioma (intraaxial expansion without well-defined margins, likely diffuse midline glioma H3 K27-altered with poor prognosis) versus focal/exophytic lesion (better-circumscribed, surgically amenable, potentially lower grade), and document compression of the fourth ventricle and presence of obstructive hydrocephalus, as these affect management strategy.